LENZ Therapeutics (LENZ) Stock

After losing some value lately, a hammer chart pattern has been formed for LENZ Therapeutics, Inc. (LENZ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences:

Does LENZ Therapeutics, Inc. (LENZ) have what it takes to be a top stock pick for momentum investors? Let's find out.

LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Dan Chevallard - CFO Eef Schimmelpennink - President and CEO Shawn Olsson - CCO Marc Odrich - CMO Conference Call Participants Yigal Nochomovitz - Citi Marc Goodman - Leerink Partners Joe Catanzaro - Piper Sandler Pavan Patel - Bank of America Lachlan Hanbury-Brown - William Blair Gary Nachman - Raymond James Matthew Caufield - H. C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the LENZ Therapeutics' Third Quarter 2024 Conference Call.

On Sunday, Corxel Pharmaceuticals and LENZ Therapeutics LENZ released topline data from the Phase 3 JX07001 trial of LNZ100 in patients with presbyopia in China.

Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment，and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). The difference in efficacy was statistically significant in the LNZ100 treatment group compared to the vehicle group (p

FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025 FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025

SAN DIEGO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences:

LENZ Therapeutics (NASDAQ: LENZ ) just reported results for the first quarter of 2024. LENZ Therapeutics reported earnings per share of -$3.53.